Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Tissing group

Our focus is to improve supportive care which is needed to help children and their families to cope with their cancer treatment, to increase quality of life and to prevent treatment related mortality. We aim to develop evidence based practical guidelines regarding supportive care topics to support the decision-making of the healthcare professionals. To achieve this goal, current and future research gaps need to be identified and studies to bridge these knowledge gaps will be performed.

Group leader: Dr. Wim Tissing

The last decades, survival of childhood cancer patients has increased substantially. However, anti-cancer treatment induces severe side effects and increases the burden of treatment for both children and parents. Supportive care is necessary to prevent or treat these side effects. 

Our research group is based at the University Medical Center Groningen (UMCG) and the Princess Máxima Center for pediatric oncology. All research topics will be translated into evidence based practical guidelines to support health care professionals. 

“We Care! - to improve prevention and treatment of chemotherapy-induced side effects for a better survival and quality of life in childhood cancer patients” Dr. Wim Tissing - Group leader
In the UMCG the group focuses on preclinical studies on pathophysiology and treatment options for gastrointestinal mucositis. Results from these studies will be further explored in clinical studies in the Princes Máxima Center for pediatric oncology. In the Princess Máxima Center for pediatric oncology the focuses are:

  1. Nutrition / body composition / physical activity
    Food intake and physical activity are affected during anti-cancer treatment. More knowledge is needed about nutritional requirements, the course of nutritional status, possible causes of inadequate food intake (i.e., smell and taste changes), and consequences of anti-cancer treatment (i.e., altered body composition) in order to develop new interventions.
  2. Infections
    Bacterial and fungal infections are an important cause of mortality during anti-cancer treatment. Better treatment options are necessary to prevent and treat this high risk pediatric population.
  3. Palliative care
    Many patients suffer from pain in the outpatient setting, with suboptimal pain management. In collaboration with the Grootenhuis group, new ways to improve communication between the patient and the hospital are studied.
  4. Nausea and vomiting
    A substantial number of patients still suffer from nausea and vomiting, despite the current anti emetic therapy options. New drugs and optimization of the existing therapy will be studied.
  5. Clinical practice guidelines, improvement of care
    To get the existing knowledge to the professional, taking care of the patients, evidence based guidelines are needed. We will develop new guidelines, and take care they are embedded in regular patient care.


To obtain our goals, we collaborate with several (inter)national groups:

  • in studies with quality of life as one of the topics of interest, we collaborate with the Grootenhuis group.
  • To develop clinical practice guidelines, we collaborate with the Kremer group.
  • To test new drugs to improve supportive care, we collaborate with the Zwaan group.
  • To improve prophylaxis and treatment of fungal infections, we collaborate with the group of Dr. R. Brüggemann at the Radboud university medical center Nijmegen.
  • To study smell and taste changes in children with cancer, we collaborate with the group of Dr. R. Havermans at the Maastricht University.
  • To develop international guidelines, we collaborate with IPOG - International guideline collaboration. 

Dr. Wim Tissing's publications can be found on PubMed.

Tissing group